Braidwell LP Guardant Health, Inc. Transaction History

Braidwell LP

$1.63 Billion
Q2 2025

A detailed history of Braidwell LP transactions in Guardant Health, Inc. stock. As of the latest transaction made, Braidwell LP holds 837,800 shares of GH stock, worth $46.2 Million. This represents 2.67% of its overall portfolio holdings.

Number of Shares

837,800

Previous 1,327,327 36.88%

Holding current value

$46.2 Million

Previous $56.5 Million 22.89%

% of portfolio

2.67%

Previous 3.47%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$37.05 - $52.04 $18.1 Million - $25.5 Million	-489,527 Reduced 36.88%	837,800 $43.6 Million
Q1 2025 May 15, 2025	SELL	$31.77 - $49.94 $48.3 Million - $75.9 Million	-1,520,604 Reduced 53.39%	1,327,327 $56.5 Million
Q4 2024 Feb 14, 2025	SELL	$20.2 - $38.11 $9.98 Million - $18.8 Million	-494,193 Reduced 14.79%	2,847,931 $87 Million
Q3 2024 Nov 14, 2024	BUY	$22.3 - $36.29 $11.9 Million - $19.4 Million	534,156 Added 19.02%	3,342,124 $76.7 Billion
Q2 2024 Aug 14, 2024	BUY	$16.07 - $31.84 $5.32 Million - $10.5 Million	331,164 Added 13.37%	2,807,968 $81.1 Billion
Q1 2024 May 15, 2024	BUY	$17.13 - $26.91 $29.4 Million - $46.2 Million	1,717,876 Added 226.36%	2,476,804 $51.1 Billion
Q4 2023 Feb 14, 2024	BUY	$21.58 - $29.5 $1.51 Million - $2.06 Million	69,928 Added 10.15%	758,928 $20.5 Billion
Q3 2023 Nov 14, 2023	BUY	$25.8 - $39.97 $10.8 Million - $16.7 Million	419,000 Added 155.19%	689,000 $20.4 Billion
Q2 2023 Aug 14, 2023	BUY	$20.94 - $38.01 $5.65 Million - $10.3 Million	270,000 New	270,000 $9.67 Billion

Others Institutions Holding GH

# of Institutions

415

Shares Held

126M

Call Options Held

1.51M

Put Options Held

2.35M

View Full List

About Guardant Health, Inc.

Ticker GH
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 102,220,000
Market Cap $5.63B
Description
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a cl...

More about GH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Braidwell LP, based on Form 13F filings with the SEC.

News

Stay updated on Braidwell LP with notifications on news.

Account